Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Post-Allogeneic Stem Cell Transplant Surveillance of CD34+ Sorted Peripheral Blood to Quantify Emergent DNMT3A, IDH and NPM1 clones and Correlation with Clinical Outcome

Shaun Fleming, MBBS(Hons) FRACP FRCPA, Nik Cummings, Tongted Das, Adam Ivey, BSc, MSc, PhD, Julie McManus, Sharon Avery, MBBS, FRACP, FRCPA, Sushrut S. Patil, FRACP, FRCPA, Patricia A. Walker, MBBS, David J. Curtis, MBBS,PhD FRACP, FRCPA, Andrew Spencer, MD, Andrew Wei, MBBS, PhD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 2674.

https://doi.org/10.1182/blood.V130.Suppl_1.2674.2674

Published: 2017

Journal Articles

Comparison of Frontline Induction Therapy Using Idarubicin in Combination with High-Dose (HDAC3) Versus Intermediate-Dose Cytarabine (IDAC3) in Adult Acute Myeloid Leukemia

Ing Soo S Tiong, MBBS, Katherine Fielding, MBBS, BMedSci, Chun Y Fong, MBBS, BMedSci, FRACP,FRCPA, Hadley Bortz, BPharm, GradCert PharmPrac, MClinPharm, MSHP, Sharon Avery, MBBS, FRACP, FRCPA, Andrew P Grigg, MBBS, MD FRACP, FRCPA, Andrew Wei, MBBS, PhD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 3868.

https://doi.org/10.1182/blood.V130.Suppl_1.3868.3868

Published: 2017

Journal Articles

Clinical Relevance of Partial Response in the Marrow (PRm) after Failure of Frontline Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML)

Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Doen Ming Ong, MBBS, Kathryn Jackson, MBBS, FRACP, FRCPA, Sharon Avery, MBBS (Hons), FRACP, FRCPA, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Paula Marlton, MBBS, FRACP, FRCPA, Glen A Kennedy, MBBS, FRACP, FRCPA, Andrew Wei, MBBS, FRACP, FRCPA, PhD

Blood (2015) 126 (23): 2512.

https://doi.org/10.1182/blood.V126.23.2512.2512

Published: 2015

Journal Articles

Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia

Anish Puliyayil Nair, MD DM, Patricia A. Walker, MBBS, FRACP, FRCPA, Anna Kalff, MBBS, FRACP, FRCPA, Krystal Bergin, MBBS, Sharon Avery, MBBS (Hons), FRACP, FRCPA, David J. Curtis, MD, PhD, Sushrut S. Patil, FRACP, FRCPA, Jenny Muirhead, Tongted Phomoonna, Daniela Klarica, RN, Andrew Spencer

Blood (2015) 126 (23): 2030.

https://doi.org/10.1182/blood.V126.23.2030.2030

Published: 2015

Journal Articles

Comparison of Cyclophosphamide/Total Body Irradiation (Cy/TBI) and Etoposide/Total Body Irradiation (Etop/TBI) Conditioned Allogeneic Stem Cell Transplant (alloHSCT) for Adult Acute Lymphoblastic Leukaemia (ALL), Data from an Australian Tertiary Care Centre

Anish Puliyayil Nair, MD DM, Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Sharon Avery, MBBS (Hons), FRACP, FRCPA, David J. Curtis, MD, PhD, Sushrut S. Patil, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Jenny Muirhead, Andrew Spencer

Blood (2015) 126 (23): 5543.

https://doi.org/10.1182/blood.V126.23.5543.5543

Published: 2015

Journal Articles

T Cell Numbers Have Prognostic Value in Acute Myeloid Leukemia with Normal Cytogenetics

Victoria Y Ling, MBBS, B. MDSci, Denise Lee, MB BS, Zoe K Mcquilten, Sharon Avery, MBBS, Michael Low, MB BS, Andrew Wei, MBBS, PhD, Stephen Cody, Trung Nguyen, Catriona McLean, Professor, Stephen Ting, MB BS, FRACP, FRCPA, PhD

Blood (2014) 124 (21): 1023.

https://doi.org/10.1182/blood.V124.21.1023.1023

Published: 2014

Journal Articles

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Philip Campbell, MBBS, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Andrew H Wei, MBBS, PhD, Anna Kalff, MBBS, FRACP, FRCPA, Jenny Muirhead, Andrew Spencer, MD

Blood (2013) 122 (21): 2128.

https://doi.org/10.1182/blood.V122.21.2128.2128

Published: 2013

Journal Articles

Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma

Philip Campbell, MBBS, FRACP, FRCPA, Tongted Das, David Kipp, Patricia A. Walker, MBBS, FRACP, FRCPA, Jenny Muirhead, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Anna Kalff, MBBS, FRACP, FRCPA, Andrew Spencer, MD

Blood (2013) 122 (21): 2129.

https://doi.org/10.1182/blood.V122.21.2129.2129

Published: 2013

Journal Articles

Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML

Andrew H Wei, MBBS, PhD, Peter T. Tan, MBBS, John Catalano, MD, Patricia A. Walker, MBBS, FRACP, FRCPA, Anthony P. Schwarer, MD, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Stephen Opat, MD, Nik Cummings, BSc, Andrew Spencer, MD

Blood (2011) 118 (21): 2599.

https://doi.org/10.1182/blood.V118.21.2599.2599

Published: 2011

Journal Articles

Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse,

Chun Yew Fong, MBBS, George Grigoriadis, MBBS, PhD, BSc, Jay Hocking, MBBS, Philip Campbell, MBBS, FRACP, FRCPA, Anthony P. Schwarer, MD, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Hatem H. Salem, MD, FRACP, FRCPA, Andrew Spencer, MD, Andrew H Wei, MBBS, PhD

Blood (2011) 118 (21): 3631.

https://doi.org/10.1182/blood.V118.21.3631.3631

Published: 2011

Journal Articles

A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,

Andrew H Wei, MBBS, PhD, Peter T. Tan, MBBS, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Anthony P. Schwarer, MD, Elchanan H. Januszewicz, MBBS, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Wai Khoon Ho, MBBS FRACP FRCPA, Constantine S. Tam, MBBS, FRACP, FRCPA, Andrew Spencer, MD

Blood (2011) 118 (21): 3625.

https://doi.org/10.1182/blood.V118.21.3625.3625

Published: 2011

Journal Articles

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

Peter T. Tan, MBBS, Kate Reed, BSc, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Othon L Gervasio, DDS, MS, PhD, Ivo J. Winiger, MD, Dirk Hönemann, MD, Andrew H Wei, MBBS, PhD, Andrew Spencer, MD

Blood (2011) 118 (21): 1529.

https://doi.org/10.1182/blood.V118.21.1529.1529

Published: 2011

Journal Articles

A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML

Andrew H Wei, MBBS, PhD, Sonali Sadawarte, John Catalano, MBBS, FRACP, FRCPA, Robert Hills, MA, MSc, DPhil, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, Alan Burnett, Andrew Spencer, MD

Blood (2010) 116 (21): 3299.

https://doi.org/10.1182/blood.V116.21.3299.3299

Published: 2010

Journal Articles

Clinical Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study

Andrew H Wei, MBBS, PhD, Sonali Sadawarte, MBBS, MD, DM, John Catalano, MBBS, FRACP, FRCPA, Anthony P. Schwarer, MD, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, Andrew Spencer, MD

Blood (2010) 116 (21): 3301.

https://doi.org/10.1182/blood.V116.21.3301.3301

Published: 2010

NARROW

Post-Allogeneic Stem Cell Transplant Surveillance of CD34+ Sorted Peripheral Blood to Quantify Emergent DNMT3A, IDH and NPM1 clones and Correlation with Clinical Outcome

Comparison of Frontline Induction Therapy Using Idarubicin in Combination with High-Dose (HDAC3) Versus Intermediate-Dose Cytarabine (IDAC3) in Adult Acute Myeloid Leukemia

Clinical Relevance of Partial Response in the Marrow (PRm) after Failure of Frontline Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML)

Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia

Comparison of Cyclophosphamide/Total Body Irradiation (Cy/TBI) and Etoposide/Total Body Irradiation (Etop/TBI) Conditioned Allogeneic Stem Cell Transplant (alloHSCT) for Adult Acute Lymphoblastic Leukaemia (ALL), Data from an Australian Tertiary Care Centre

T Cell Numbers Have Prognostic Value in Acute Myeloid Leukemia with Normal Cytogenetics

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma

Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML

Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse,

A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML

Clinical Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only